—Biopharma Commercial Strategy
Commercial Value Doesn’t Start at Approval.
It Starts Now.
Senior commercial advisor for biopharma leadership teams from first clinical decision through launch. The right commercial perspective, at the right moment.
— What We Do
The commercial perspective your pipeline deserves
01 - Build a stronger asset
Commercial thinking entered early produces better development decisions and a more credible story for investors, partners, and the market.
02 - Inform the decisions that matter most
The Phase II to Phase III transition is the most consequential commercial decision point in a drug’s development. We provide the perspective needed before the protocol is locked.
03 - Prepare for the conversations ahead
Whether you’re heading into an investor meeting, a partnering discussion, or launch preparation — Lucera helps you walk in with a commercial narrative that holds up under scrutiny.
— Areas of Engagement
From Ideation to commercial Launch
Engagements are calibrated to your stage — focused and selective early, more intensive as critical decisions approach
PoC to Phase I
Target patient population and value hypothesis before defining clinical assumptions.
Target Product Profile
A commercially grounded TPP guiding toward a viable outcome.
Pivotal Phase II/III
Commercial input into endpoint(s) and label strategy before trial design & protocol are solidified.
Product Narrative
Translating clinical data into a Value Proposition narrative that resonates with all audiences.
Investors
Stress-testing the commercial assumptions before meeting with sophisticated audiences.
Late Phase III
US and international launch strategy & execution; Long-Term commercial and Lifecycle planning.
—About Lucera
Built on real commercial Expertise
Lucera was founded on a simple observation: the most important commercial decisions in a drug's development happen years before launch — and most development-stage companies don't have the right experience in the room when those decisions are made.
Our founder brings 15+ years of Pharma commercial leadership to every engagement, including direct responsibility managing household names such as Lipitor and one of the most demanding rare disease/hematology portfolios in the industry.
—Why Lucera
Expertise that Matters
Direct US and international launch experience across multiple therapeutic categories, including muti-billion dollar products and portfolios
Management consulting and finance background — evaluating assets the way investors and acquirers do
Commercial development at scale — including Lipitor, cardiovascular/metabolic portfolio, infectious diseases, and rare hematology portfolios
Therapeutic experience across rare disease, cardiovascular, metabolic, diabetes, hematology, and hospital specialty
Direct, objective counsel, including when the answer is more complicated than expected
Not sure where to start?
A single conversation is usually enough to identify where commercial input would add the most value to your program.